ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene…
Articles by Margarida Maia, PhD
Switching to Jivi (damoctocog alfa pegol), an extended half-life replacement therapy, from Kovaltry (octocog alfa), may help adults…
Sarcopenia, or loss of muscle mass and strength, may occur in as many as half of adults with severe…
A real-world study in Spain found that, among hemophilia patients, those with hemophilia A may have have worse joint…
Individually tailored prophylaxis, or preventive treatment, with Jivi (damoctocog alfa pegol) nearly halved the number of annual bleeding episodes…
The first patient has been dosed in China in a registrational clinical trial of BBM-H803, a one-time investigational gene therapy…
SerpinPC, an experimental treatment being developed by Centessa Therapeutics, continues to be safe when used for up to nearly…
GS1191, a gene therapy in the pipeline of Gritgen Therapeutics, increased factor VIII (FVIII) activity in the blood of…
People with hemophilia are living longer, but Black males still are more likely to die from the disease, and…
Switching from on-demand treatment to regular preventive therapy with extended half-life products may mean fewer bleeds, healthier joints, and better…